Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenströms macroglobulinaemia (WM).
Purity:
98.50%
CAS Number:
[1372645-37-8]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
